Objective: We compiled the largest dataset of seroconverter cohorts to date from 25
countries across Africa, North America, Europe, and Southeast/East (SE/E) Asia to …

Introduction It is unknown whether HIV treatment guidelines, based on resource-rich country
cohorts, are applicable to African populations. Methods We estimated CD4 cell loss in ART …

Introduction Model‐based estimates of key HIV indicators depend on past epidemic trends
that are derived based on assumptions about HIV disease progression and mortality in the …

Background Some individuals remain AIDS-free with a high and stable CD4 cell count
without antiretroviral therapy (ART) for many years. We estimated long-term progression-free …

We studied repeated measurements of CD4 cell counts on 5739 HIV-1–infected individuals
with reliably estimated dates of seroconversion (SC) aged≥ 15 years at SC prior to initiation …

Introduction Several methods have been proposed to estimate the time of HIV
seroconversion, including those based on CD4 cell depletion models. However, previous …

Background: Studies based on seroconverters have increased our understanding of HIV
disease. It is not clear, however, whether their disease progression differs from that of the …

Objectives To investigate factors that predict speed of recovery and long‐term CD 4 cell
count in HIV‐1 seroconverters initiating combination antiretroviral therapy (cART), and to …

Background We estimated the time from human immunodeficiency virus (HIV)
seroconversion to antiretroviral therapy (ART) initiation during an era of expanding HIV …

Background: The relationship between CD4+ T-cell counts determined soon after
seroconversion with HIV-1 (baseline CD4), nadir CD4, and CD4 levels attained during …